EKTERLY

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 18 Jun 2025 filing date already counts against anyone who files later.

Record

Serial number

79429992

Mark type

Design + words

Filed

18 Jun 2025

Published for opposition

07 Apr 2026

Attorney of record

Stacy L. Wu

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders; pharmaceutical preparations containing sebetralstat for the treatment of angioedema, hereditary angioedema, bradykinin mediated inflammatory disorders, plasma kallikrein or factor XIIa mediated diseases or disorders, or diseases and disorders mediated by the contact activation system

Owner

• Kalvista Pharmaceuticals Limited, Wiltshire, GB

Prosecution history

• 02 Apr 2026 — NOTIFICATION PROCESSED BY IB
• 01 Apr 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 19 Mar 2026 — REFUSAL PROCESSED BY IB
• 18 Mar 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
• 18 Mar 2026 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
• 10 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 04 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 04 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 04 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 28 Feb 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 28 Feb 2026 — REFUSAL PROCESSED BY MPU
• 31 Jan 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
• 30 Jan 2026 — NON-FINAL ACTION WRITTEN
• 30 Jan 2026 — ASSIGNED TO EXAMINER
• 29 Jan 2026 — APPLICATION FILING RECEIPT MAILED